Not FDA-approved1Evidence: Animal and lab onlyTissue repair and wound healing · Inflammation and immune

KPV1

Also called Lys-Pro-Val1

Key takeaway

KPV is a three-amino-acid peptide (lysine, proline and valine) related to a natural hormone, and the research on it comes from animal and laboratory studies.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no product containing it authorized in the European Union.1 FDA found no studies of KPV in people at all, so its effects and safety in humans are unknown.1 FDA staff recommended against adding KPV to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6

KPV at a glance

What it isA peptide of three amino acids: lysine, proline and valine. Research FDA reviewed describes it as the end segment of alpha-melanocyte-stimulating hormone.1
FDA statusNot FDA-approved. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, KPV acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidenceNone found. FDA identified no clinical studies or other human exposure data for KPV.1
Evidence strengthAnimal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned

What is KPV?

KPV is a small peptide made of three amino acids: lysine (K), proline (P) and valine (V). Research FDA reviewed describes it as the final three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a natural hormone with anti-inflammatory effects.1

FDA could not determine how long or how widely KPV has been used in compounding. Outsourcing facilities reported no products containing it from 2017 to June 2025.1

FDA found websites promoting KPV for inflammatory and gut conditions, wound healing and skin health, sometimes combined with other peptides such as BPC-157 and TB-500.1

How is KPV thought to work?

How KPV works has not been established. FDA’s briefing states that the molecular targets behind its reported effects remain unknown.1

Unlike the full hormone it comes from, KPV did not appear to act through the hormone’s usual melanocortin receptors in laboratory studies. Researchers have proposed that it may dampen inflammatory signaling inside cells instead.1

FDA found no pharmacokinetic studies showing how KPV is absorbed or handled by the body.1

What do human studies show?

There are none in FDA’s review. FDA evaluated KPV for wound healing and inflammatory conditions and found no clinical studies or other human exposure data for KPV by any route.1

The nine references submitted to FDA in support of KPV were animal studies of related hormone fragments and one laboratory study in donated human skin.1

FDA’s searches of its adverse-event databases through December 2025 found no reports involving KPV.1

FDA concluded that there is a lack of evidence to evaluate whether KPV works for the proposed uses and that its safety risks in people are unknown.1

What the evidence base contains

  • Animal or laboratory research Rodent and cell studies reporting anti-inflammatory and wound-healing effects. FDA notes that the molecular targets behind these effects remain unknown.1
  • Animal or laboratory research A laboratory study in donated human skin that found KPV does not pass well through the skin’s outer layer.1

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is KPV FDA-approved?

No. FDA’s May 2026 evaluation states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5

FDA staff evaluated both forms of KPV for that list for wound healing and inflammatory conditions and recommended against adding either. They cited poor chemical characterization, unknown extent of use, no human data on safety or effectiveness, and existing FDA-approved treatments.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists KPV among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.3

HHS’s policy document states that KPV was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6

FDA’s Pharmacy Compounding Advisory Committee discussed KPV on July 23, 2026. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For KPV, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6

HHS and FDA staff weigh the same record differently. HHS’s policy document says use of KPV is now documented, that newer test results for the acetate form supply what FDA staff found missing, and that FDA staff’s safety conclusion reflects an absence of information rather than an observed harm. FDA staff had found no human data at all.1,6

The policy does not make KPV an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6

Timeline

  1. In September 2023, KPV is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
  2. A Federal Register notice announces the July advisory-committee meeting that will discuss KPV and opens a public comment docket.4
  3. KPV leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
  4. FDA staff date their evaluation recommending that KPV not be added to the 503A bulks list.1
  5. FDA’s Pharmacy Compounding Advisory Committee discusses KPV.2
  6. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists KPV among six peptide substances used in compounding.5,6

What is still unknown?

Whether KPV has any benefit in people: FDA found no human studies of it for any condition.1

Its safety in people, how it is absorbed, and whether it can trigger immune reactions.1

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1

Whether FDA’s rulemaking will add KPV to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for KPV: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for KPV are the records PeptideScanner has selected and published, not every registration or paper about KPV. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not an FDA-approved drug. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Official evidence assessment

What does the official evidence assessment say?

FDA assessment dated May 12, 2026 · Read September 15, 2026 · Preserved version 1

FDA's assessment of KPV free base and KPV acetate for the nominated uses of wound healing and inflammatory conditions. The assessment was prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting. FDA document ↗

What did FDA find about human studies?

FDA reported that its search did not identify studies of KPV administered to humans. It concluded that evidence was insufficient to evaluate effectiveness for the nominated uses. FDA pp. 20, 21 ↗

Why human skin research is different

FDA identified a skin-permeation study using human cadaver skin among the nomination references. That is not a study of KPV treatment in living participants. FDA pp. 20 ↗

What is known about harms?

FDA reported no identified human pharmacokinetic studies or clinical safety studies. Its adverse-event searches through December 3, 2025 did not identify qualifying reports; the agency states that potential safety risks in humans are unknown. FDA pp. 25, 26 ↗

Scope, source pin and remaining work

This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.

Source: FDA briefing document for KPV. SHA-256: 0253b86534700fc72a48cccab7b10c19201102da831ef7a8a28e8dab09fea254.

Open versioned assessment data →

Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

The nominated evidence was not a human treatment program

FDA’s July 2026 briefing found that the submitted references concerned animal work or skin permeation using human cadaver skin. These are distinct from administering KPV to living participants. FDA PDF pp. 20 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

The absence claim has a defined source and scope

FDA reported finding no clinical studies supporting KPV for wound healing or inflammatory conditions in its evaluation. This is an attributed search finding, not proof that no relevant record could exist anywhere. FDA PDF pp. 20, 21 ↗

Safety remains uncharacterized in the reviewed evidence

The briefing found no human pharmacokinetic or clinical safety studies. Its adverse-event search retrieved no reports, but FDA explicitly explains why passive reporting cannot establish safety. FDA PDF pp. 26 ↗

Quality questions matter even for a short peptide

FDA identified missing characterization and formulation data and insufficient information about aggregation and immunogenicity. A three-amino-acid sequence alone did not resolve those product-level questions. FDA PDF pp. 27, 28 ↗

What remains to be checked

  • Check subsequent advisory records and any final FDA action separately from the staff briefing.
  • Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA kpv briefing for the July 2026 advisory meeting ↗

    Source dated 2026-07-23; retrieved 2026-09-19.

    • The nominated evidence was not a human treatment program · PDF pp. 20 of 38
    • The absence claim has a defined source and scope · PDF pp. 20, 21 of 38
    • Safety remains uncharacterized in the reviewed evidence · PDF pp. 26 of 38
    • Quality questions matter even for a short peptide · PDF pp. 27, 28 of 38

    SHA-256: 0253b86534700fc72a48cccab7b10c19201102da831ef7a8a28e8dab09fea254

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.

128 retrieved · 0 included · 128 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"KPV"[Title/Abstract] OR "Lys-Pro-Val"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T13:04:50.086500+00:00 · HTTP 200 · SHA-256 eaa4d3fe4ab20414a5ead879b11a0179d951450d9b5a19612bbb6a32cf71f36e.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T13:04:52.499645+00:00 · HTTP 200 · SHA-256 baf3e40647c186121cfab1332e29f62ac68da0eda8b7552c5f50fc58597513a1.

  • All 128 records returned by this exact title/abstract query were screened for administration of the defined KPV tripeptide to people. None met that criterion; this does not establish absence outside this query.
  • Citation follow-up, other aliases, trial registries and non-indexed reports remain separate coverage work. Preclinical evidence and related molecules require their own scopes.

Showing 25 of 128 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 42585803 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  2. PubMed 42064835 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  3. PubMed 41880199 — exclude: Secondary overview of mechanisms or potential applications; not a primary human-administration report.
  4. PubMed 41533788 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  5. PubMed 41241376 — exclude: Secondary overview of mechanisms or potential applications; not a primary human-administration report.
  6. PubMed 41209547 — exclude: Secondary overview of mechanisms or potential applications; not a primary human-administration report.
  7. PubMed 40935835 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  8. PubMed 40073467 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  9. PubMed 40030207 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  10. PubMed 39252648 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  11. PubMed 39211778 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  12. PubMed 38289234 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  13. PubMed 38041747 — exclude: Different molecule, longer sequence, acronym or name match; not administration of the defined KPV tripeptide to people.
  14. PubMed 37860176 — exclude: Different molecule, longer sequence, acronym or name match; not administration of the defined KPV tripeptide to people.
  15. PubMed 37859689 — exclude: Full-text eligibility review identifies male C57BL/6J mice in the KPV-conjugate acute and chronic colitis experiments (sections 2.5.4 and 2.5.5); not administration to people.
    Full-text eligibility check · PMC10582360

    Read the source full text ↗ · sections 2.5.4, 2.5.5.

    This reading establishes eligibility for this search; it is not a full appraisal of the study.

    Reviewed 2026-09-15; source SHA-256 7a3158245d0f6a0d4d23c128e6d9b41efb84e006120275de1deb364f466ceb1a.

  16. PubMed 37508552 — exclude: Secondary overview of mechanisms or potential applications; not a primary human-administration report.
  17. PubMed 37161053 — exclude: Different molecule, longer sequence, acronym or name match; not administration of the defined KPV tripeptide to people.
  18. PubMed 36240893 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  19. PubMed 35496263 — exclude: Different molecule, longer sequence, acronym or name match; not administration of the defined KPV tripeptide to people.
  20. PubMed 35245681 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  21. PubMed 34846053 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  22. PubMed 34662120 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  23. PubMed 34547895 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  24. PubMed 32004526 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.
  25. PubMed 31408067 — exclude: Laboratory, structural, cell/tissue or animal research in the inspected abstract; no administration of the defined KPV tripeptide to people is described.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"KPV"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:16.981646+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["KPV", "Lys-Pro-Val"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["KPV", "Lys-Pro-Val"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["KPV", "Lys-Pro-Val"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "KPV" OR "Lys-Pro-Val"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:26:15.363786+00:00 · HTTP 200 · SHA-256 b54968c05ff881a1ef7ce604b6a340248f8e2aee8637bef06da0f5693f520df8.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

            Explore status sources, recent additions, and coverage gaps

            Living status brief

            What is the current status of KPV?

            Not an FDA-approved drug. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.↗↗↗↗

            The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

            Evidence present

            What records are connected here?

            Evidence lanes
            2
            Source years
            7
            Drugs@FDA applications
            0

            These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

            Coverage gaps

            What remains unknown or unsupported?

            PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

            PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

            Explore the Evidence Map and record counts

            Evidence Map v1

            What kinds of records connect to KPV?

            Compare collection coverage →

            This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

            13Selected dated records
            23Connected citations
            7Populated source years2003–2026
            2/4Record lanes present

            Registered human studies

            Trial composition

            0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

            PubMed bibliography

            Publication composition

            0 of 11 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

            Bibliography fields unavailable here for 11 selected records; the records remain visible as metadata observations.

            Regulatory and publication surfaces

            What is structurally connected?

            Drugs@FDA applications
            0
            FDA Federal Register documents
            1
            DailyMed SPL versions
            0
            Canonical profile
            Published
            Profile structured data
            Published
            Linked dated records
            13

            Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

            Profile publication history and record counts
            Source records by collection · 13 dated records

            Research hub

            Explore the KPV evidence record

            Open all 13 records →
            13Dated records
            2Evidence types
            20Cited public sources
            7Source years

            Change ledger

            Recently changed for KPV

            Open all 15 events →

            PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

            Profile status changed

            KPV profile

            We added a plain-language reader guide with cited answers, re-checked FDA’s KPV briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists KPV acetate. FDA has not issued a final 503A rule.

            PeptideScanner change date
            November 14, 2026
            Evidence lane
            Profile
            Record added

            Federal Register notice 2026-07361

            The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.

            PeptideScanner change date
            August 21, 2026
            Cited source date
            April 16, 2026
            Evidence lane
            Regulatory

            Official-source collections

            Source records for KPV

            Open the full research atlas →

            Evidence types

            Coverage by source year

            Selected records span November 14, 2003 to July 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

            Continue exploring

            Profiles with overlapping source-year coverage

            Open the research atlas →

            These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

            Organizations and trial records named in cited sources

            Organizations named in cited records

            • U.S. Food and Drug Administration1,2
            • U.S. Department of Health and Human Services5
            Dated updates connected to this profile · 13

            Updates connected to this profile

            Open the full cross-source timeline →
            1. Regulatory

              FDA committee met on seven peptide-related groups of bulk drug substances↗

              FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗

            2. Regulatory

              Federal Register notice 2026-07361↗

              The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗

            3. Literature metadata

              PubMed record PMID 39252648↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 39252648 at 2026-07-30T16:25:12.445Z. PubMed recorded a metadata revision date of 2026-02-17 and an Entrez history date of 2024-09-10. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            4. Literature metadata

              PubMed record PMID 27458604↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 27458604 at 2026-07-30T18:28:30.778Z. PubMed recorded a metadata revision date of 2025-05-30 and an Entrez history date of 2016-07-27. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            5. Literature metadata

              PubMed record PMID 34846053↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 34846053 at 2026-07-30T19:56:20.406Z. PubMed recorded a metadata revision date of 2021-12-23 and an Entrez history date of 2021-11-30. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            6. Literature metadata

              PubMed record PMID 34547895↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 34547895 at 2026-07-30T19:58:34.757Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2021-09-22. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            7. Literature metadata

              PubMed record PMID 22837805↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 22837805 at 2026-07-30T19:58:22.828Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2012-07-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            8. Literature metadata

              PubMed record PMID 25298219↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 25298219 at 2026-07-30T20:43:08.957Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2014-10-10. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            9. Literature metadata

              PubMed record PMID 29953505↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 29953505 at 2026-07-30T21:09:28.939Z. PubMed recorded a metadata revision date of 2018-12-19 and an Entrez history date of 2018-06-29. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            10. Literature metadata

              PubMed record PMID 18092346↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 18092346 at 2026-07-30T21:10:56.892Z. PubMed recorded a metadata revision date of 2018-09-13 and an Entrez history date of 2007-12-20. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            11. Literature metadata

              PubMed record PMID 28343991↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 28343991 at 2026-07-30T21:12:28.720Z. PubMed recorded a metadata revision date of 2018-04-05 and an Entrez history date of 2017-03-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            12. Literature metadata

              PubMed record PMID 15102092↗

              PeptideScanner retained PubMed bibliographic metadata for PMID 15102092 at 2026-07-30T21:56:55.933Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2004-04-23. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗

            Citations

            Sources

            Coverage and sources →

            Numbered markers in the text point here. Each link opens the original public record.

            1. 1
              FDA briefing document for KPV ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            2. 2
              July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            3. 3
              Certain bulk drug substances for use in compounding that may present significant safety risks ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            4. 4
              Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

              Federal Register via GovInfo · Official source · Source checked August 21, 2026

            5. 5
              Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

              Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

            6. 6
              HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

              U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026